A major new study suggests popular weight-loss drugs may also protect against breast cancer.
Researchers analyzed health records from over 111,000 overweight or obese women. The study compared those with and without exposure to GLP-1 agonists, like semaglutide.
The results showed a significant difference. Breast cancer was diagnosed in 1.62% of women taking the drugs versus 2.47% of those not on them. After statistical matching for factors like age, race, and diabetes history, the analysis confirmed a 30.5% lower incidence linked to the medication.
This protective effect held across racial subgroups. The findings point to a potential new avenue for cancer prevention, as traditional options often have serious side effects.
Experts say the exact reason is unclear. The drugs may directly inhibit tumors or reduce inflammation, independent of weight loss.
The study is observational and cannot prove causation. Scientists are now calling for definitive randomized trials to confirm the potential for breast cancer prevention.